Screener
Inhibrx Biosciences, Inc. INBX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Inhibrx Biosciences, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026. Open the filing →
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
FAQ
- What is Inhibrx Biosciences, Inc.'s debt-to-equity?
- Inhibrx Biosciences, Inc. (INBX) reported debt-to-equity of 13.4× in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s debt-to-equity changed year-over-year?
- Inhibrx Biosciences, Inc.'s debt-to-equity increased by 22139.5% year-over-year, from 0.1× to 13.4×.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s debt-to-equity?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s debt-to-equity has grown at a 66.5% compound annual growth rate (CAGR), from 4.8× to 13.4×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Inhibrx Biosciences, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude